KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Capital Expenditures (2016 - 2024)

Arbutus Biopharma's Capital Expenditures history spans 12 years, with the latest figure at $86000.0 for Q4 2024.

  • For Q4 2024, Capital Expenditures changed N/A year-over-year to $86000.0; the TTM value through Sep 2025 reached $86000.0, down 10.42%, while the annual FY2024 figure was $182000.0, 81.94% down from the prior year.
  • Capital Expenditures for Q4 2024 was $86000.0 at Arbutus Biopharma, up from $1000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $859000.0 in Q2 2023 and bottomed at $1000.0 in Q2 2024.
  • The 5-year median for Capital Expenditures is $91000.0 (2022), against an average of $161176.5.
  • The largest annual shift saw Capital Expenditures skyrocketed 857.58% in 2021 before it tumbled 99.88% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at $152000.0 in 2020, then crashed by 61.84% to $58000.0 in 2021, then soared by 131.03% to $134000.0 in 2022, then tumbled by 76.12% to $32000.0 in 2023, then surged by 168.75% to $86000.0 in 2024.
  • Per Business Quant, the three most recent readings for ABUS's Capital Expenditures are $86000.0 (Q4 2024), $1000.0 (Q2 2024), and $95000.0 (Q1 2024).